Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review

被引:110
作者
Johansson, BA [1 ]
Berglund, M
Lindgren, A
机构
[1] Lund Univ, Univ Hosp MAS, Dept Clin Alcohol Res, S-20502 Malmo, Sweden
[2] Lund Univ, Ctr Math Sci, Dept Math Stat, Malmo, Sweden
关键词
maintenance treatment; meta-analysis; naltrexone; opioid dependence; psychosocial intervention; RCT; retention;
D O I
10.1111/j.1360-0443.2006.01369.x
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims To determine the efficacy of naltrexone in reducing illicit opioid use and the potential moderating role of treatment retention. Design First, randomized controlled trials (RCTs) comparing the regimens of treatment using the opioid antagonist, naltrexone, with controls were analysed by meta-analysis for treatment effect with regard to a range of outcome criteria. The degree of heterogeneity was also determined. The moderating effect of other interventions during naltrexone maintenance was then estimated, particularly with regard to their effect on treatment retention. Participants Fifteen studies involving 1071 patients were found. Measurements All available outcomes were analysed in 10 studies of naltrexone versus control (seven placebo) and six studies of randomized psychosocial/psychopharmacological interventions. Findings Significant heterogeneity was found in the efficacy of naltrexone. Level of retention in treatment was found to be a moderator, explaining most of the heterogeneity found. Overall, naltrexone was significantly better than control conditions in reducing the number of opioid-positive urines. This effect was only present in the high retention subgroup for differences in retention. Contingency management (CM) increased retention and naltrexone use, resulting in a reduced number of opioid-positive urines. Conclusion Retention is important to the effect of naltrexone in treating opioid dependence. Contingency management is a promising method of increasing retention.
引用
收藏
页码:491 / 503
页数:13
相关论文
共 43 条
[21]  
JOHANSSON BA, 2003, TREATING ALCOHOL DRU, P465
[22]   A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence [J].
Kirchmayer, U ;
Davoli, M ;
Verster, AD ;
Amato, L ;
Ferri, M ;
Perucci, CA .
ADDICTION, 2002, 97 (10) :1241-1249
[23]  
KIRCHMAYER U, 1999, COCHRANE LIB
[24]  
KIRCHMAYER U, 2002, COCHRANE LIB
[25]  
KIRCHMAYER U, 2001, COCHRANE LIB
[26]   Naltrexone for heroin dependence treatment in St. Petersburg, Russia [J].
Krupitsky, EM ;
Zvartau, EE ;
Masalov, DV ;
Tsoi, MV ;
Burakov, AM ;
Egorova, VY ;
Didenko, TY ;
Romanova, TN ;
Ivanova, EB ;
Bespalov, AY ;
Verbitskaya, EV ;
Neznanov, NG ;
Grinenko, AY ;
O'Brien, CP ;
Woody, GE .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2004, 26 (04) :285-294
[27]  
LADEWIG D, 1990, THER UMSCH, V47, P247
[28]   A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts [J].
Landabaso, MA ;
Iraurgi, I ;
Jimenez-Lerma, JM ;
Sanz, J ;
De Corres, BF ;
Araluce, K ;
Calle, R ;
Gutierrez-Fraile, M .
ADDICTION, 1998, 93 (05) :739-744
[29]  
LERNER A, 1992, ISRAEL J PSYCHIAT, V29, P36
[30]  
MELLO NK, 1981, J PHARMACOL EXP THER, V216, P45